GeneDx (NASDAQ:WGS) CEO Sells $195,669.03 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 3,639 shares of the company’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $53.77, for a total value of $195,669.03. Following the transaction, the chief executive officer directly owned 96,123 shares in the company, valued at $5,168,533.71. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, April 29th, Katherine Stueland sold 2,172 shares of GeneDx stock. The stock was sold at an average price of $65.19, for a total value of $141,592.68.
• On Thursday, March 26th, Katherine Stueland sold 46,933 shares of GeneDx stock. The shares were sold at an average price of $63.17, for a total transaction of $2,964,757.61.
• On Monday, March 16th, Katherine Stueland sold 17,179 shares of GeneDx stock. The shares were sold at an average price of $76.80, for a total transaction of $1,319,347.20.

GeneDx Stock Down 1.8%

WGS stock opened at $59.92 on Friday. The firm has a 50 day moving average of $54.95 and a 200 day moving average of $90.19. The stock has a market capitalization of $1.78 billion, a PE ratio of -22.36 and a beta of 1.96. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. GeneDx Holdings Corp. has a 52 week low of $32.21 and a 52 week high of $170.87.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The company had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same period in the prior year, the firm posted ($0.23) EPS. Sell-side analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp boosted its holdings in GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares during the last quarter. Kestra Advisory Services LLC purchased a new position in shares of GeneDx during the 4th quarter valued at about $27,000. Fifth Third Bancorp purchased a new position in shares of GeneDx during the 1st quarter valued at about $31,000. Quarry LP lifted its holdings in shares of GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after buying an additional 209 shares during the period. Finally, Ramirez Asset Management Inc. purchased a new stake in shares of GeneDx in the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Hedge fund manager Eli Casdin is reportedly adding to his GeneDx position, which may be seen as a sign that some sophisticated investors still view the stock as undervalued. Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
• Neutral Sentiment: Several law firms continue to remind investors about the pending securities class action and the August 3 lead-plaintiff deadline. These notices keep the lawsuit in focus, but do not add new operational developments. Investor Alert: Pomerantz Law Firm Reminds Investors…
• Neutral Sentiment: Additional legal updates from Rosen, Faruqi & Faruqi, Schall, Robbins, and others reinforce the litigation backdrop tied to GeneDx’s Fabric Genomics acquisition and the Q1 2026 selloff. ROSEN, TOP RANKED INVESTOR COUNSEL…
• Negative Sentiment: GeneDx CEO Katherine Stueland and CFO Kevin Feeley both sold shares this week. The company says the sales were for tax withholding tied to vesting equity awards, but insider selling can still weigh on sentiment. CEO Form 4 Filing
• Negative Sentiment: The biggest overhang remains the securities class action alleging GeneDx misled investors about reimbursement rates, margin pressure, and the impact of the Fabric Genomics acquisition after a major stock drop and write-off tied to the deal. GeneDx Holdings (WGS) Faces Securities Class Action…

Wall Street Analysts Forecast Growth

WGS has been the subject of a number of research analyst reports. BTIG Research reduced their target price on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Canaccord Genuity Group set a $75.00 price target on GeneDx and gave the company a “buy” rating in a research note on Tuesday, May 5th. Craig Hallum reissued a “buy” rating and issued a $85.00 price objective on shares of GeneDx in a report on Tuesday, May 5th. Wells Fargo & Company restated an “overweight” rating and issued a $75.00 price objective (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Finally, Guggenheim decreased their target price on GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and an average price target of $96.43.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.